The FDA had resolved the shortage of Wegovy in April, and telehealth providers were advised to stop selling compounded ...

A new injectable weight loss treatment from the maker of Ozempic and Wegovy delivered 23% weight loss in trials, according to ...

The Wegovy maker says the telehealth company didn't stop selling compounded versions of the blockbuster drug after Novo ...

While the makers of Ozempic have stated that its GLP-1 medication was not made to be used as a weight loss drug, nor should ...

Novo Nordisk said Hims & Hers has “failed to adhere to the law which prohibits mass sales of compounded drugs” under the ...

Novo Nordisk’s new weight-loss drug helped patients lose even more weight on average than its current Wegovy blockbuster ...

The effect of Novo Nordisk’s amycretin injections on body weight showed no signs of plateauing after 36 weeks, suggesting the ...

Shares in Novo Nordisk fell as much as 3.5% on Monday after detailed trial data on its experimental obesity drug CagriSema ...

Novo Nordisk ends partnership with Hims & Hers over compounded Wegovy, shaking the market. See why I recommend a wait-and-see ...

Amycretin, a new weight-loss treatment from Novo Nordisk, combines two hunger hormones, helping participants lose nearly ...

At a time when Novo Nordisk has appeared to be slipping behind rival Eli Lilly and its blockbuster Zepbound (tirzepatide) in ...